Measuring hsCRP - An important part of a comprehensive risk profile or a clinically redundant practice?

PLoS Medicine

Volumn 7, Issue 2, 2010, Pages

  McCormack, James P ^a   Allan, G Michael ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; C REACTIVE PROTEIN; CHOLESTEROL; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; ROFECOXIB; ROSIGLITAZONE; ROSUVASTATIN; BIOLOGICAL MARKER; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MEDICAL PRACTICE; OUTCOME ASSESSMENT; PREDICTION; REVIEW; RISK ASSESSMENT; AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; EVIDENCE BASED MEDICINE; FEMALE; IMMUNOLOGY; MALE; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; TREATMENT OUTCOME; UNNECESSARY PROCEDURE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PREDICTIVE VALUE OF TESTS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SULFONAMIDES; TREATMENT OUTCOME; UNNECESSARY PROCEDURES;

EID: 77449150839     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000196     Document Type: Review

References (36)

1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207.
2. Woloshin S, Schwartz LM (2005) Distribution of C-reactive protein values in the United States. N Engl J Med 352: 1611-1613.
3. Mitka M (2003) Panel endorses limited role for CRP tests. JAMA 289: 973-974.
4. Grundy SM, Hansen B, Smith SC, Jr., Cleeman JI, Kahn RA (2004) Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109: 551-556.
5. Bard RL, Rubenfire M, Eagle K, Clarke NS, Brook RD (2005) Utility of C-reactive protein measurement in risk stratification during primary cardiovascular disease prevention. Am J Cardiol 95: 1378-1379.
6. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR (2008) C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118: 2243-2251.
7. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, et al. (2001) Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47: 444-450.
8. Macy EM, Hayes TE, Tracy RP (1997) Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43: 52-58.
9. Campbell B, Badrick T, Flatman R, Kanowski D (2002) Limited clinical utility of high-sensitivity plasma C-reactive protein assays. Ann Clin Biochem 39: 85-88.
10. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, et al. (2006) An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 166: 1368-1373.
11. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, et al. (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355: 2631-2639.
12. Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, et al. (2009) Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 38: 217-231.
13. (2009) Reynold's Risk Score. Available: http://www.reynoldsriskscore.org/ . Accessed 30 March 2009.
14. Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121: 293-298.
15. Reynolds TM, Twomey P, Wierzbicki AS (2002) Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk 9: 183-190.
16. Cook NR, Buring JE, Ridker PM (2006) The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 145: 21-29.
17. Wilson PWF, Pencina M, Jacques P, Selhub J, D'Agostino R Sr, et al. (2008) C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 1: 92-97.
18. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278.
19. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158.
20. (2009) Theheart.org. Available: http://www.theheart.org/editorial- program/926043.do. Accessed 30 March 2009.
21. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, et al. (2005) Randomized trials stopped early for benefit: a systematic review. JAMA 294: 2203-2209.
22. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373: 1175-1182.
23. Prasad K (2006) C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 24: 33-50.
24. Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298: 1189-1195.
25. Monakier D, Mates M, Klutstein MW, Balkin JA, Rudensky B, et al. (2004) Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest 125: 1610-1615.
26. Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, et al. (2004) Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation 110: 934-939.
27. McCormack JP, Rangno R (2002) Digging for data from the COX-2 trials. CMAJ 166: 1649-1650.
28. Keech A, Simes RJ, Barter P, Best J, Scott R, et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849-1861.
29. (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102: 21-27.
30. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ (2003) Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 361: 2017-2023.
31. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297: 842-857.
32. (1975) Clofibrate and niacin in coronary heart disease. JAMA 231: 360-381.
33. Sager PT, Capece R, Lipka L, Strony J, Yang B, et al. (2005) Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 179: 361-367.
34. Ka s t e l e i n J J , Akdim F, St r oes ES , Zwinderman AH, Bots ML, et al. (2008) Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358: 1431-1443.
35. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117-125.
36. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, et al. (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344: 1959-1965.